Sector News

Researchers identify new genetic clues for ‘silent’ strokes

March 27, 2021
Life sciences

New research has discovered genetic clues in people who have had small, ‘silent’ strokes that could enable the development of new treatments for the condition.

The research, funded by the British Heart Foundation (BHF), identified changes to 12 genetic regions in the DNA of people who have had a lacunar stroke – this type of stroke is caused by a weakening of the small blood vessels deep in the brain.

Following this type of stroke, damage to the blood vessels and interruption to blood flow can cause difficulty with thinking, memory, walking and ultimately lead to dementia.

Prior to this research, only one genetic fault had been associated with lacunar strokes.

The research team, led by Professor Hugh Markus and his team at the University of Cambridge working with international researchers, now hope their findings could enable the discovery of new treatments for lacunar stroke and vascular dementia.

The researchers scanned and compared the genetic code of 7,338 patients who had a lacunar stroke with 254,798 people who had not.

After this, they discovered many of the 12 genetic regions linked to lacunar strokes were involved in maintaining the neurovascular unit.

These genetic changes are believed to make the small blood vessels ‘leakier’ and cause toxic substances to enter the brain.

The research team, based on their findings, will now plan to test if new treatments can correct these abnormalities on brain cells in the lab, with hopes to begin human clinical trials in the next ten years.

“These small and often silent lacunar strokes have gone under the radar for a long time, and so we haven’t been able treat patients as well as we’d like to. Although small, their consequences for patients can be enormous,” said Professor Markus, BHF-funded researcher, leader of the study and neurologist at the University of Cambridge.

“We now plan to use this new genetic blueprint as a springboard to develop much needed treatments to prevent lacunar strokes from occurring in the first place and to help stave off dementia,” he added.

by Lucy Parsons

Source: pharmatimes.com

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach